Obinutuzumab for chronic lymphocytic leukemia: Promise of the first treatment approved with breakthrough therapy designation

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 5, 2015, Pages 358-363

  Kakkar, Ashish Kumar ^a   Balakrishnan, Sadasivam ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti CD20; Breakthrough therapy Designation; Chronic Lymphocytic Leukemia; Obinutuzumab

Indexed keywords

CHLORAMBUCIL; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL DEATH; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; DRUG CLEARANCE; DRUG COST; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFUSION RELATED REACTION; LEUKEMIA REMISSION; LEUKOPENIA; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; DISEASE FREE SURVIVAL; DRUG APPROVAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; DRUG APPROVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84940107983     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214534868     Document Type: Review

References (15)

1. Altekruse SF, Kosari CL, Krapcho M,. SEER clinical statistics review, 1975-2007, Bethesda, MD: National Cancer Institute, 2010.
2. Press Announcements-FDA approves Gazyva for chronic lymphocytic leukemia, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373209.htm (accessed 15 Nov 2013).
3. FDA, Dept. of Health & Human Services, Guidance for Industry: expedited programs for serious conditions- drugs and biologics, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf (accessed 30 Nov 2013).
4. EMA. Guideline on the procedure for accelerated assessment pursuant to Article 14 (9) of regulation (EC) No 726/2004, http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500004136.pdf (accessed 25 Mar 2014).
5. EMA. Guideline on the scientific application and the practical arrangements necessary to implement commission regulation (EC) No 507/2006 on the conditional marketing authorisation for Medicinal products for human use falling within the scope of Regulation (EC) No 726/2004, http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/10/WC500004908.pdf (accessed 26 Mar 2014).
6. Horning SJ, Haber DA, Selig WKD,. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013; 19: 4297-4304.
7. EMA. Parallel scientific advice with the Food and Drug Administration, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000049.jsp&mid=WC0b01ac05800229b9 (accessed 26 Mar 2014).
8. Mössner E, Brünker P, Moser S,. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402.
9. Niederfellner G, Lammens A, Mundigl O,. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118: 358-367.
10. US FDA. Clinical Review BLA 125486/0, http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/125486Orig1s000MedR.pdf (accessed 30 Nov 2013).
11. Goede V. Head-To-Head Comparison of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb in Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage II Results of the CLL11 Trial, https://ash.confex.com/ash/2013/webprogram/Paper60276.html (2013, accessed 18 Dec 2013).
12. Gazyva (obinutuzumab): US prescribing information, http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2013/125486s000lbl.pdf (2013, accessed 11 Dec 2013).
13. US FDA. Clinical Pharmacology Secondary Review of Gazyva, http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/125486Orig1s000ClinPharmR.pdf (accessed 12 Dec 2013).
14. Red Book Online, http://www.redbook.com/redbook/online (accessed 27 Mar 2014).
15. Walzer S, Becker U, Samanta K,. The potential cost-effectiveness of obinutuzumab (Ga101) in combination with chlorambucil in chronic lymphocytic leukemia. Value Health 2013; 16: A412-A412.